Skip to content

Vivani Medical VANI Neuromodulation Division — Total Assets

Other segment segments

Biopharm Division
$41.9M+20.7%
Neurostimulation Division
$500K

Similar metrics at other companies

LivaNova logo
LIVNNeuromodulation — Total Assets
$650.1M+1.3%
Nutex Health Inc. logo
NUTXPopulation health management division — Total Assets
$30.78M+12.9%
OSI Systems logo
OSISOptoelectronics And Manufacturing Division — Total Assets
$298.9M+2.9%
Fulgent Genetics, Inc. logo
FLGTTherapeutic Development — Total Assets
$109.14M+22.8%
Asset Entities logo
ASSTMedical Device — Total Assets
$17.63M
Abbott logo
ABTNutritional Products — Total Assets
$4.9B+5.8%

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's neuromodulation division — total assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's neuromodulation division — total assets?
Vivani Medical (VANI) reported neuromodulation division — total assets of $500K in Q1 2026.
What does neuromodulation division — total assets mean?
This metric represents the total economic resources controlled by the Neuromodulation Division, including tangible and intangible assets dedicated to its operations. It provides insight into the scale of the division's infrastructure and the capital intensity required to support its neuromodulation business. Investors use this to evaluate the asset base supporting the division's growth and market presence.